Effect of pharmacogenetic-based selection of first-line chemotherapy on response rate and R0 surgery in metastatic CRC patients.
Albert Abad, Eva Martinez‐Balibrea, José María Viéitez(Hospital Universitario Central de Asturias), Ramón Salazar(Institut Català d'Oncologia), José Luís Manzano(Badalona Serveis Assistencials), Vicente Alonso(Instituto de Investigación Sanitaria Aragón), Manuel Benavides(Hospital Clínico Universitario Virgen de la Victoria), Jordi Remón(Vall d'Hebron Hospital Universitari), Pilar Alfonso, Enrique Aranda(Instituto Maimónides de Investigación Biomédica de Córdoba), Manuel Gallén(Hospital Del Mar), Alfredo Carrato(Hospital General Universitario de Elche), Javier Sastre(Hospital Clínico San Carlos), V. Conde(Hospital Universitario Virgen de las Nieves), Fernando Rivera(Marqués de Valdecilla University Hospital), Mariano Provencio(Hospital Universitario Puerta de Hierro Majadahonda), Manuel Valladares(American Society of Clinical Oncology), Bartomeu Massutí(Universitat de Miguel Hernández d'Elx), Cristina Grávalos Castro(Research Institute Hospital 12 de Octubre), Javier Gállego(Hospital General Universitario de Elche)
Cited by 2
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k